Lilly shares falter after quarterly earnings report

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.

The Indianapolis-based drugmaker, which announced its quarterly results Monday morning, recorded restructuring charges due to its downsizing as it tries to develop new drugs to help it shrug off its looming patent expirations.

Lilly earned $1.1 billion, or 95 cents per share, during the three months ended March 31. Those results were at least 15 percent lower than during the same quarter a year ago.

However, excluding charges related to the company’s downsizing and higher research costs from drug development partnerships, Lilly would have earned $1.24 per share.

Analysts surveyed by Thomson Reuters, who typically exclude special charges from their forecasts, were expecting $1.16 per share.

The surprise seemed to matter little to investors, as Lilly’s stock fell as much as 1.8 percent in morning trading,  to $35.37 per share. The Dow Jones industrial average fell as much as 2 percent Monday morning after a bond rating agency cut its outlook on U.S. government debt.

Also, analysts focused on Lilly’s longer-term challenges: its best-selling drug, Zyprexa, will lose patent protection in October, costing Lilly most of its $5 billion in annual sales to cheaper generic copies.

"Granted, it's always good when quarterly earnings are better than expected, but the question on investors' minds is how Lilly will fare post-Zyprexa," Miller Tabak analyst Les Funtleyder told the Reuters news agency.

Because one of Lilly’s blockbusters, the cancer drug Gemzar, already lost patent protection late last year, and because two other big products, Cymbalta and Evista, will face generic competitors in the next three years, the company stands to lose roughly $10 billion in sales.

Lilly officials have tried to focus investors on the areas of the company that are and will continue to grow. Its volume of sales in Japan rose 34 percent in the quarter. Its volume of China sales rose 23 percent. And its animal health business grew 25 percent.

And Lilly officials emphasized that they now have 69 experimental drugs in human testing, including nine in Phase 3, the final stage before submitting for market approval.

“So far, 2011 is playing out as anticipated,” said Derica Rice, Lilly’s chief financial officer. He added, “This pipeline serves as the foundation of our growth [after 2014].”

First-quarter sales at Lilly rose 6 percent, to $5.8 billion, mainly on the strength of international sales. Analysts were expecting revenue of $5.7 billion.

Lilly lowered its full-year profit forecast about 6 cents per share—to reflect its restructuring charges. It now expects to earn $3.86 to $4.01 per share.

Lilly spent $76.3 million on severance as it continued its efforts to trim 5,500 workers by year’s end. The company said it is 75 percent of the way toward that goal.

Lilly also spent another $26 million on its restructuring efforts. And two research partnerships—with Germany-based Boehringer Ingelheim and with Australia-based Acrux Ltd.—cost the company $438 million in the quarter.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...